Patient view: Getting lung cancer patient voices heard in health technology appraisals
This article was originally published in Scrip
Lung cancer patients should have a louder voice in NICE health technology appraisals, say patient advocates as another new drug –Pfizer's Xalkori (crizotinib) – looks set to be rejected by the HTA.
You may also be interested in...
Insurers argue that better use of real world data and multiple pricing assessments could help lower drug prices in Germany.
To keep investors happy, companies will have to start showing that their high-priced advanced therapies offset costs elsewhere in the health care system.
To maintain high prices and avoid access restrictions, companies marketing advanced therapies will have to show payers that their products save money elsewhere in the healthcare system.